Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience

MeSH terms

• Aged
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Dexamethasone / administration & dosage*
• Dexamethasone / adverse effects
• Doxorubicin / administration & dosage*
• Doxorubicin / adverse effects
• Drug Resistance, Neoplasm / drug effects
• Female
• Follow-Up Studies
• Humans
• Lenalidomide
• Male
• Middle Aged
• Multiple Myeloma / drug therapy*
• Multiple Myeloma / mortality
• Recurrence
• Thalidomide / administration & dosage
• Thalidomide / adverse effects
• Thalidomide / analogs & derivatives*
• Treatment Outcome